Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366185 | 0.93 | CRHR1 (0.48) | CRHR1DPP4DPP8HSD11B1 | |
| SCHEMBL3364753 | 0.88 | CRHR1 (0.50) | CRHR1DPP4DPP8HSD11B1 | |
| SCHEMBL6024733 | 0.86 | CRHR1 (0.48) | CRHR1HSD11B1 | |
| SCHEMBL3839128 | 0.84 | CRHR1 (0.51) | CRHR1HSD11B1 | |
| SCHEMBL3364574 | 0.83 | CRHR1 (0.50) | CRHR1HSD11B1 | |
| SCHEMBL4701738 | 0.83 | CRHR1 (0.41) | CRHR1F2RL3 | |
| SCHEMBL3841160 | 0.83 | CRHR1 (0.45) | CRHR1HSD11B1 | |
| SCHEMBL3363727 | 0.82 | CRHR1 (0.47) | CRHR1HSD11B1 | |
| Hydrochloric Acid SCHEMBL3362608 | 0.81 | CRHR1 (0.46) | CRHR1HSD11B1 | |
| SCHEMBL4700567 | 0.81 | CRHR1 (0.42) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | CRHR1 1/4885DPP4 2415/4885DPP8 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.